Drug intelligence / Profile preview

BCMA targeted prime CAR-T cells

Development stage: Phase 2
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BCMA targeted prime CAR-T cells is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Chongqing Precision Biotech Co., Ltd. This biological intervention is designed to treat patients with relapsed/refractory Multiple Myeloma and Plasma Cell Disease. The therapy involves genetically engineering a patient's own T cells to express a CAR that specifically recognizes and binds to B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells. This binding initiates an immune response, leading to the destruction of the cancerous cells.

Other names: BCMA targeted prime CAR-T cells

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on BCMA targeted prime CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCMA targeted prime CAR-T cells.

Explore the full profile